Imigran

Sumatriptan succinate, the active ingredient in Imigran, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients. It works by causing cranial blood‑vessel constriction and inhibiting the release of pro‑pain neuropeptides, providing rapid relief of headache and associated symptoms.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for each batch.

Imigran (sumatriptan) acts on the serotonergic pathway to treat migraine and related headache disorders. - Migraine with aura: rapid relief of headache, nausea, photophobia and phonophobia. - Migraine without aura: reduction of headache intensity and associated symptoms. - Acute cluster headache: alleviation of severe unilateral head pain during an attack.

Sumatriptan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Chest tightness or pressure: a transient sensation of heaviness in the chest that usually resolves quickly. - Tingling or numbness in the face or extremities: mild paresthesia affecting lips, tongue, fingers or toes. - Nausea or abdominal discomfort: mild gastrointestinal upset that may accompany the headache relief.

Serious or Rare Side Effects: - Coronary artery spasm or myocardial infarction: severe cardiac events that require immediate medical attention. - Serotonin syndrome when combined with other serotonergic drugs: potentially life‑threatening condition marked by agitation, hyperthermia, and neuromuscular abnormalities. - Severe allergic reaction (anaphylaxis): rapid onset of hives, swelling, breathing difficulty, and shock.

Before prescribing Imigran, clinicians should evaluate the following precautionary considerations. - Cardiovascular disease: avoid use in patients with coronary artery disease, angina or recent myocardial infarction. - Uncontrolled hypertension: contraindicated in individuals with systolic BP >160 mmHg or diastolic >100 mmHg. - History of stroke or transient ischemic attack: not recommended due to risk of cerebral vasoconstriction. - Concomitant serotonergic agents: caution when combined with SSRIs, SNRIs, MAO inhibitors or other triptans. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct sunlight.

Sumatriptan may interact with other medicines, and certain combinations should be avoided or closely monitored.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome when used together. - SSRIs, SNRIs, or other serotonergic drugs: increased chance of serotonin syndrome. - Ergot alkaloids: additive vasoconstrictive effects may precipitate ischemia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: can increase sumatriptan exposure and prolong its action.